Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer

Manavi Sachdeva1, David S P Tan1,2

  • 1Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore, Singapore.

Abstract